In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring

References

• Powell DJ, Jr, Rosenberg SA. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother 2004; 27: 36–47
   PubMedGoogle Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321–7
   PubMed Web of Science ®Google Scholar
• Slingluff CL, Jr. Tumor antigens and tumor vaccines: peptides as immunogens. Semin Surg Oncol 1996; 12: 446–53
   Google Scholar
• Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80: 219–30
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451–8
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909–15
   PubMed Web of Science ®Google Scholar
• Coulie PG, Karanikas V, Lurquin C, et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002; 188: 33–42
   PubMed Web of Science ®Google Scholar
• Lonchay C, van der Bruggen P, Connerotte T, et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 2004; 101(Suppl 2)14631–8
   PubMedGoogle Scholar
• Coulie PG, van der Bruggen P. T-cell responses of vaccinated cancer patients. Curr Opin Immunol 2003; 15: 131–7
   PubMed Web of Science ®Google Scholar
• Jackson HM, Dimopoulos N, Chen Q, et al. A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. J Immunol Meth 2004; 291: 51–62
   PubMedGoogle Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–52
   PubMed Web of Science ®Google Scholar
• Nijman HW, Houbiers JGA, Vierboom MPM, et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 1993; 23: 1215–9
   PubMedGoogle Scholar
• Henderson RA, Michel H, Sakaguchi K, et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992; 255: 1264–6
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63: 789–99
   PubMed Web of Science ®Google Scholar
• Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45: 321–34
   PubMed Web of Science ®Google Scholar
• Britten CM, Meyer RG, Kreer T, et al. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods 2002; 259: 95–110
   PubMed Web of Science ®Google Scholar
• Mannering SI, McKenzie JL, Hart DN. Optimisation of the conditions for generating human DC initiated antigen specific T lymphocyte lines in vitro. J Immunol Methods 1998; 219: 69–83
   Google Scholar
• Yee C, Savage PA, Lee PP, et al. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999; 162: 2227–34
   PubMed Web of Science ®Google Scholar
• Valmori D, Dutoit V, Lienard D, et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 2000; 60: 4499–506
   PubMed Web of Science ®Google Scholar
• Bonini C, Lee SP, Riddell SR, et al. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol 2001; 166: 5250–7
   PubMed Web of Science ®Google Scholar
• Coulie PG, Karanikas V, Colau D, et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001; 98: 10290–5
   PubMed Web of Science ®Google Scholar
• Bacchetta R, Sartirana C, Levings MK, et al. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol 2002; 32: 2237–45
   PubMed Web of Science ®Google Scholar
• Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 2003; 4: 579–85
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Lee PP, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003; 111: 639–47
   PubMed Web of Science ®Google Scholar
• Alexander-Miller MA, Derby MA, Sarin A, et al. Supraoptimal peptide-major histocompatibility complex causes a decrease in Bcl-2 levels and allows tumor necrosis factor alpha receptor II- mediated apoptosis of cytotoxic T lymphocytes. J Exp Med 1998; 188: 1391–9
   PubMed Web of Science ®Google Scholar
• Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996; 93: 4102–7
   PubMed Web of Science ®Google Scholar
• Rogers PR, Dubey C, Swain SL. Qualitative changes accompany memory T cell generation: faster, more effective responses at lower doses of antigen. J Immunol 2000; 164: 2338–46
   PubMed Web of Science ®Google Scholar
• Paczesny S, Banchereau J, Wittkowski KM, et al. Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med 2004; 199: 1503–11
   PubMed Web of Science ®Google Scholar
• Misko IS, Soszynski TD, Kane RG, et al. Factors influencing the human cytotoxic T cell response to autologous lymphoblastoid cell lines in vitro. Clin Immunol Immunopathol 1984; 32: 285–97
   Google Scholar
• Misko IS, Sculley TB, Schmidt C, et al. Composite response of naive T cells to stimulation with the autologous lymphoblastoid cell line is mediated by CD4 cytotoxic T cell clones and includes an Epstein-Barr virus-specific component. Cell Immunol 1991; 132: 295–307
   Google Scholar
• Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003; 3: 269–79
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Finkelstein SE, Surman DR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 2004; 101: 1969–74
   PubMed Web of Science ®Google Scholar
• Schluns KS, Williams K, Ma A, et al. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol 2002; 168: 4827–31
   PubMed Web of Science ®Google Scholar
• Vella AT, Dow S, Potter TA, et al. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 3810–5
   PubMed Web of Science ®Google Scholar
• Judge AD, Zhang X, Fujii H, et al. Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells. J Exp Med 2002; 196: 935–46
   PubMedGoogle Scholar
• Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25: 97–138
   PubMed Web of Science ®Google Scholar
• Hobeika AC, Morse MA, Osada T, et al. Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC tetramer, ELISpot, and intracellular cytokine analysis. J Immunother 2005; 28: 63–72
   PubMed Web of Science ®Google Scholar